In the general news, Paris was attacked again by terrorists, causing President Hollande to declare war on ISIS. Meanwhile, a U.S. drone vaporized Jihadi John, and Kurdish forces took back the northern Iraqi city of Sinjar.
In healthcare business news, Mylan (MYL) failed at the hostile $26 B takeover of Perrigo (PRGO). Express Scripts (ESRX) removed from the formulary drugs made by Horizon Pharma (HZNP) because they were using Linden Care specialty pharmacy to sell their products exclusively, ignoring cheaper alternatives, ala Valeant (VRX) and Philidor. Merck (MRK) acquired Harrisvaccines. Lastly, Safeway (SWY) cancelled its partnership with Theranos.
On the data front, the Fall meetings were in high gear. Portola’s (PTLA) drug andexanet alfa to reverse the anticoagulation effects of Xarelto succeeded. Cytokinetics’ (CYTK) and Amgen’s (AMGN) drug omecamtiv mecarbil was promising in heart failure. Alnylam’s (ALNY) and Medicines Co (MDCO) cholesterol drug ALN-PCSsc posted early results, poised to compete with AMGN’s Repatha and REGN/Sanofi’s Praluent. Novo Nordisk’s (NVO) diabetes drug Victoza failed to reduce heart failure. Lastly, Sophiris Bio’s (SPHS) prostate cancer drug PRX302 succeeded.
From the FDA, the agency approved Roche’s Cotellic as part of a cocktail therapy with Zelboraf for melanoma. AstraZeneca (AZN) won approval for Tagrisso (osimertinib) to treat EGFR lung cancer. Lastly, Baxalta’s (BXLT) drug for hemophilia type A, Adynovate, was approved.